BJMO - volume 9, issue 3, july 2015
T. Vermassen PhD, P. de Visschere MD, G. Villeirs MD, PhD, D. Schrijvers MD, PhD, S. Rottey MD, PhD
Due to the success of last year, a second national Belgian multidisciplinary scientific meeting on urological cancers was held with the cooperation of medical oncologists (BSMO), urologists (BAU) and radiation oncologists (ABRO/BVRO). It was a great opportunity to build bridges between these three important specialisations involved in the treatment of urological cancers.
The steering committee of the meeting consisted of J. P. Machiels, G. Pelgrims, S. Rottey (members of BSMO); L. Hoekx, S. Joniau, T. Roumeguere (members of BAU); O. De Hertogh, G. De Meerleer and Y. Neybuch (members of ABRO/BVRO). The second meeting, held in Brussels on March 28th, 2015 was a great success with more than 100 attendees of the different specialisations involved.
In this meeting report you will find summaries of the lectures of Dr De Visschere (Radiologist) and Dr Schrijvers (Medical Oncologist).
(BELG J MED ONCOL 2015;9(3):113–16)
Read moreBJMO - volume 6, issue 3, june 2012
A. Smeets MD, PhD, B. Carly MD, V. Cocquyt MD, PhD, M. Vanhoeij , C. Bourgain MD, PhD, E. Lifrange MD, PhD, G. Villeirs MD, PhD, M. De Ridder MD, PhD, M. Drijkoningen MD, PhD, J. Lamote , R. Van Den Broecke , M. Voordeckers , J. De Grève MD, PhD, P. Neven MD, PhD, M.R. Christiaens
The aim of this article is to highlight the recent changes in the surgical approach of the axilla in breast cancer patients. Axillary staging is dominated by the sentinel lymph node (SLN) biopsy, which is now widely practiced in clinically node negative patients. Most authors believe a SLN biopsy may even be performed in patients with a large or multifocal tumour, before neo-adjuvant systemic therapy, during pregnancy, after prior excisional biopsy and after prior mantle field radiotherapy of the breast. Intra-operative assessment of the SLN is recommended as it can identify half of all positive lymph nodes. It is generally accepted that it is safe to omit an axillary lymph node dissection (ALND) in patients with a negative SLN or with only isolated tumour cells (<0.2 mm) in the SLN. Moreover, in a subset of patients with a micro-/macrometastasis in the SLN it might not be necessary to perform a completion of ALND. We suggest to accept the option of omitting completion of ALND in frail patients with a positive sentinel lymph node on final pathology OR in these patients with, on final pathology, one or two positive SLNs AND a grade I or II tumour smaller than 4 cm AND adjuvant radiotherapy on the whole breast or chest wall. In conclusion, an increasingly tailored surgical approach is guiding the management of the axilla for women with early breast cancer. (BELG J MED ONCOL 2012;6:87–95)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
